Yahoo Web Search

Sign In

Search results

  1. ir.ionis.com › news-releases › news-release-detailsIonis announces olezarsen FCS New Drug Application accepted for...

    Jun 25, 2024 · Ionis is planning additional regulatory filings for the treatment of FCS in the European Union this year. In addition to FCS, Ionis is evaluating olezarsen for the treatment of severe hypertriglyceridemia (sHTG) in three Phase 3 clinical trials – CORE, CORE2 and ESSENCE, all three of which completed enrollment in the first half of ...

  2. www.prnewswire.com › news-releases › ionis-announces-olezarsenIonis announces olezarsen FCS New Drug Application accepted for...

    Jun 25, 2024 · In addition to FCS, Ionis is evaluating olezarsen for the treatment of severe hypertriglyceridemia (sHTG) in three Phase 3 clinical trials – CORE, CORE2 and ESSENCE, all three of which completed...

  3. Videos

    View all

  4. www.morningstar.com › stocks › XNASIONS Stock Price Quote | Morningstar

    Jun 28, 2024 · See the latest Ionis Pharmaceuticals Inc stock price (IONS:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

    • 7.37
    • 6.75
    • −3.53

  5. finance.yahoo.com › news › fda-accepts-ionis-ions-ndaFDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen

    Jun 26, 2024 · Ionis Pharmaceuticals IONS announced that the FDA accepted the new drug application (NDA), seeking approval for its investigational RNA-targeted therapy olezarsen as a potential treatment for...

  6. Top stories

    View all

  7. finance.yahoo.com › news › ionis-announces-olezarsen-fcs-drugIonis announces olezarsen FCS New Drug Application accepted for...

    Jun 25, 2024 · Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for olezarsen, an...

  8. markets.businessinsider.com › news › stocksIonis Pharmaceuticals: A Strong Buy on Regulatory Milestones and...

    Jun 26, 2024 · Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics...

  9. ir.ionis.com › news-releases › news-release-detailsIonis announces expanded licensing agreement with Otsuka in Asia...

    Jun 18, 2024 · Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema. June 18, 2024 at 7:00 AM EDT. Otsuka will be responsible for commercialization efforts for donidalorsen across both Asia Pacific and Europe.